

7 RECOMMENDATIONS FOR A NEW ECONOMIC MODEL TO INCENTIVIZE INNOVATION, MEET PRESERVATION GOALS AND ENSURE ACCESS TO ANTIBIOTICS

1



Provide **attractive and predictable prospects** of Return on Investment (ROI) to encourage further investments.

2



Reward risk-taking for both small and large companies.

3



Envisage Antibiotics R&D as a system by incentivizing both the bringing of a new medicine to registration and continued development.

4



Reward innovation by **taking into account the societal value** of having new antibiotics available in advance of resistance rates needing them.

5



Meet preservation goals by preventing usage volume incentives.

6



Be applicable at a **global level**.

7



Facilitate **access to all patients** with infections resistant to other antibiotics.

IFPMA MEMBERS' ANTIBACTERIAL COMPOUNDS PIPELINE INVENTORY 2015

KEY NUMBERS



Total number of antibacterial compounds in development:

34



Number of IFPMA member companies involved:

11

PROPORTION OF MOLECULES AND VACCINES



STAGES OF DEVELOPMENT OF ANTIBACTERIAL COMPOUNDS



15

compounds target Gram-negative bacteria. Gram-negative bacteria are generally more resistant to antibiotics than Gram-positive bacteria.

For more information please visit IFPMA website at www.ifpma.org/resources/publications.html